Home › Funds › Fairmount Funds Management LLC › ORKA
Fairmount Funds Management LLC position in ORKA
ORUKA THERAPEUTICS INC · Health Care
Fairmount Funds Management LLC reported holding 3,705,262 shares of ORKA (ORUKA THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$352.6M, representing 23.31% of its reported portfolio and ranking #1 among its reported holdings. Fairmount Funds Management LLC has disclosed ORKA holdings in 8 of the last 8 reported quarters, going back to Q3 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Fairmount Funds Management LLC's ORKA position evolved
Fairmount Funds Management LLC first disclosed a stake in ORKA in Q3 2024 at 3,211,922 shares (US$78.7M). The position peaked in Q2 2026 at 3,705,262 shares, worth US$352.6M. Across 8 filings, Fairmount Funds Management LLC increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 5 time(s). The most recent filing (Q2 2026) shows 3,705,262 shares valued at US$352.6M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2024 | 3.21M | $78.72M | New |
| Q4 2024 | 3.37M | $65.38M | Add |
| Q1 2025 | 3.37M | $34.60M | Hold |
| Q2 2025 | 3.37M | $37.80M | Hold |
| Q3 2025 | 3.71M | $71.25M | Add |
| Q4 2025 | 3.71M | $112.31M | Hold |
| Q1 2026 | 3.71M | $181.74M | Hold |
| Q2 2026 | 3.71M | $352.63M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ORKA and 13F data
ORKA (ORUKA THERAPEUTICS INC) is a Health Care company. 98 other funds we track also report a position in ORKA — the largest reported positions include Venrock Adviser, LLC (US$394.8M), RTW INVESTMENTS, LP (US$298.7M), Paradigm Biocapital Advisors LP (US$204.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ORKA
- Venrock Adviser, LLC 4.15M sh · $394.81M · Q2 2026
- RTW INVESTMENTS, LP 3.14M sh · $298.74M · Q2 2026
- Paradigm Biocapital Advisors LP 2.14M sh · $204.09M · Q2 2026
- Deep Track Capital, LP 1.93M sh · $183.30M · Q2 2026
- Bellevue Group AG 1.66M sh · $157.71M · Q2 2026
- Remedium Capital Partners, LLC 1.57M sh · $149.00M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 1.55M sh · $147.95M · Q2 2026
- PERCEPTIVE ADVISORS LLC 1.35M sh · $128.01M · Q2 2026
- Avidity Partners Management LP 760.42K sh · $72.37M · Q2 2026
- SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC 658.30K sh · $62.65M · Q2 2026
- Affinity Asset Advisors, LLC 590.00K sh · $56.15M · Q2 2026
- Cormorant Asset Management, LP 533.34K sh · $50.76M · Q2 2026
More on Fairmount Funds Management LLC
FAQ
How long has Fairmount Funds Management LLC held ORKA?
Fairmount Funds Management LLC has disclosed ORKA holdings in 8 of the last 8 reported quarters, going back to Q3 2024.
What is Fairmount Funds Management LLC's current position in ORKA?
As of Q2 2026, Fairmount Funds Management LLC holds 3.71M shares of ORKA (ORUKA THERAPEUTICS INC), valued at $352.63M, representing 23.31% of its reported portfolio and ranking #1.
Has Fairmount Funds Management LLC been buying or selling ORKA?
In the latest 13F filing (Q2 2026), Fairmount Funds Management LLC held unchanged its position in ORKA. The position peaked in Q2 2026 at 3.71M shares.
Which other funds hold ORKA?
Other major institutional holders of ORKA include Venrock Adviser, LLC, RTW INVESTMENTS, LP, Paradigm Biocapital Advisors LP, among 98 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.